Control of plasma uric acid in adults at risk for tumor lysis syndrome: Efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone - Results of a multicenter phase III study

Journal of Clinical Oncology

Volumn 28, Issue 27, 2010, Pages 4207-4213

  Cortes, Jorge ^a   Moore, Joseph O ^a   Maziarz, Richard T ^a   Wetzler, Meir ^a   Craig, Michael ^a   Matous, Jeffrey ^a   Luger, Selina ^a   Dey, Bimalangshu R ^a   Schiller, Gary J ^a   Pham, Dat ^a   Abboud, Camille N ^a   Krishnamurthy, Muthuswamy ^a   Brown Jr , Archie ^a   Laadem, Abderrahmane ^a   Seiter, Karen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; RASBURICASE; URIC ACID; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; URATE OXIDASE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RISK; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPHAGIA; DYSURIA; FATIGUE; FEMALE; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERSENSITIVITY REACTION; HYPERURICEMIA; HYPOCALCEMIA; HYPONATREMIA; INJECTION SITE IRRITATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE TWITCH; MYALGIA; OPEN STUDY; PAIN; PARESTHESIA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; ADOLESCENT; BLOOD; BLOOD DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; HYPERURICEMIA; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; UNITED STATES; URATE OXIDASE; URIC ACID; YOUNG ADULT;

EID: 77957934731     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.8896     Document Type: Article

References (23)

1. Coiffier B, Altman A, Pui CH, et al: Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 26:2767-2778, 2008
2. Hochberg J, Cairo MS: Tumor lysis syndrome: Current perspective. Haematologica 93:9-13, 2008 (Pubitemid 351156145)
3. Cairo MS, Bishop M: Tumour lysis syndrome: New therapeutic strategies and classification. Br J Haematol 127:3-11, 2004 (Pubitemid 39331101)
4. Hande KR, Garrow GC: Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 94:133-139, 1993 (Pubitemid 23046437)
5. Oda M, Satta Y, Takenaka O, et al: Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 19:640-653, 2002 (Pubitemid 34521296)
6. Arrambide K, Toto RD: Tumor lysis syndrome. Semin Nephrol 13:273-280, 1993 (Pubitemid 23144159)
7. Jones DP, Stapleton FB, Kalwinsky D, et al: Renal dysfunction and hyperuricemia at presentation and relapse of acute lymphoblastic leukemia. Med Pediatr Oncol 18:283-286, 1990 (Pubitemid 20219919)
8. Andreoli SP, Clark JH, McGuire WA, et al: Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: Relationship to acute renal failure. J Pediatr 109:292-298, 1986 (Pubitemid 16032526)
9. Pochedly C: Hyperuricemia in leukemia and lymphoma. Postgrad Med 55:93-99, 1974
10. Stokes DN: The tumour lysis syndrome: Intensive care aspects of paediatric oncology. Anaesthesia 44:133-136, 1989
11. Aloprim (allopurinol sodium) for injection [package insert]. Boca Raton, FL, Nabi, 2003
12. Zyloprim (allopurinol) [package insert]. San Diego, CA, Prometheus Laboratories, 2003
13. Smalley RV, Guaspari A, Haase-Statz S, et al: Allopurinol: Intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 18:1758-1763, 2000 (Pubitemid 30220555)
14. Goldman SC, Holcenberg JS, Finklestein JZ, et al: A randomized comparison between ras-buricase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 97:2998-3003, 2001
15. Elitek (rasburicase) [package insert]. Bridgewater, NJ, sanofi-aventis, 2008
16. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994 (Pubitemid 24273002)
17. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
18. Harris NL, Jaffe ES, Diebold J, et al: Lymphoma classification: From controversy to consensus - The R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 11:3-10, 2000 (suppl 1)
19. Newcombe RG: Interval estimation for the difference between independent proportions: Comparison of eleven methods. Stat Med 17:873-890, 1998
20. Montesinos P, Lorenzo I, Martín G, et al: Tumor lysis syndrome in patients with acute myeloid leukemia: Identification of risk factors and development of a predictive model. Haematologica 93:67-74, 2008 (Pubitemid 351156153)
21. Givens ML, Wethern J: Renal complications in oncologic patients. Emerg Med Clin North Am 27:283-291, 2009
22. Yang H, Rosove MH, Figlin RA: Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 62:247-250, 1999
23. Lin TS: Novel agents in chronic lymphocytic leukemia: Efficacy and tolerability of new therapies. Clin Lymphoma Myeloma 8:S137-S143, 2008 (suppl 4)